sunvozertinib
dizal pharmaceuticals
['sunvozertinib', 'sclc', 'nsclc']
impressive phase 2 activity for sunvozertinib in egfr ex20 mut nsclc with 61% orr and 44% intracranial orr in post-platinum setting, appears to compare favorably with ami and mobo in the 2l+ setting #asco23 
Medical oncology fellow @MSKcancercenter, prior @oslerresidency @harvardmed @yale. Precision medicine, thoracic cancers, Miami sports.